[2] LBA3: Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. [3] Lee, Ann Y. "Patterns and timing of ...
an analysis from the phase III KEYNOTE-716 trial has shown significant improvement in the secondary endpoint of distant metastasis–free survival with adjuvant pembrolizumab vs placebo in resected stage IIB or IIC cutaneous melanoma.
Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyonddoi:10.21037/atm-23-839Melanomaimmunotherapyadjuvant therapyLanyi Nora ChenRichard D. CarvajalAnnals of Translational Medicine
In KEYNOTE-716, when KEYTRUDA was administered as a single agent to patients with stage IIB or IIC melanoma, adverse reactions occurring in patients with stage IIB or IIC melanoma were similar to those occurring in 1011 patients with stage III melanoma from KEYNOTE-054. In KEY...
(28%). In KEYNOTE-716, when KEYTRUDA was administered as a single agent to patients with stage IIB or IIC melanoma, adverse reactions occurring in patients with stage IIB or IIC melanoma were similar to those occurring in 1011 patients with stage III melanoma from KEYNOTE-054...
[1] Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial - Merck.com [2] LBA3: Pembrolizumab versus placebo after complete resection ...
基于KEYNOTE-716研究的结果,美国食品与药物管理局(FDA)于今年8月初批准了帕博利珠单抗用于辅助治疗IIB和IIC期黑色素瘤完全切除患者的许可申请。帕博利珠单抗填补了高危II期黑色素瘤术后辅助治疗的空白,有效降低术后患者RFS,持续延长患者生存期。期待帕博利珠单抗在中国黑色素瘤人群中的数据及更多免疫治疗研究的前沿数据...
Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care Spotlight News Media Conferences Events Partners Publications Resources Biomarker Consortium SubscribeAdvertisement Practical Perspectives in the Treatment of Small-Cell Lung Cancer : Ep...
with KEYTRUDA was diarrhea (28%). In KEYNOTE-716, when KEYTRUDA was administered as a single agent to patients with stage IIB or IIC melanoma, adverse reactions occurring in patients with stage IIB or IIC...
with KEYTRUDA was diarrhea (28%). In KEYNOTE-716, when KEYTRUDA was administered as a single agent to patients with stage IIB or IIC melanoma, adverse reactions occurring in patients with stage IIB or IIC melanoma were similar to those occurring in 1011 patients with stage III melanoma from ...